1 NVX-CoV2373 (marketed as Nuvaxoid) is a protein-based vaccine against SARS-CoV-2, approved in Canada for adults unable or unwilling to receive an mRNA vaccine
Protein-based vaccines have a long history of use that may make them more acceptable to patients who are hesitant to receive mRNA vaccination. (1) NVX-CoV2373 consists of a recombinant spike protein subunit plus adjuvant. It may also be considered for people who are allergic to components of mRNA vaccines (e.g., polyethylene glycol). (2)
2 NVX-CoV2373 can be used in a primary series of vaccination
NVX-CoV2373 can be administered in a 2-dose primary series or as a heterologous primary series with another approved vaccine against SARS-CoV-2. Doses should be separated by 8 weeks to maximize immune response. (2)
3 NVX-CoV2373 may be offered as a booster
Although not approved by Health Canada for this indication, the National Advisory Committee on Immunizations recommends NVX-CoV2373 as a booster 6 months after any primary series....